Institut Curie, PSL Research University, Radiation Oncology Department, Proton Therapy Centre, Centre Universitaire, 91898, Orsay, France.
Institut Curie, PSL Research University, University Paris Saclay, Inserm U 1021-CNRS UMR 3347, 91898, Orsay, France.
Sci Rep. 2020 Apr 27;10(1):7025. doi: 10.1038/s41598-020-63975-9.
Proton minibeam radiation therapy (pMBRT) is a novel dose delivery method based on spatial dose fractionation. pMBRT has been shown to be promising in terms of reduced side effects and superior tumour control in high-grade glioma-bearing rats compared to standard irradiation. These findings, together with the recent optimized implementation of pMBRT in a clinical pencil beam scanning system, have triggered reflection on the possible application to patient treatments. In this context, the present study was designed to conduct a first theoretical investigation of the clinical potential of this technique. For this purpose, a dedicated dose engine was developed and used to evaluate two clinically relevant patient treatment plans (high-grade glioma and meningioma). Treatment plans were compared with standard proton therapy plans assessed by means of a commercial treatment planning system (ECLIPSE-Varian Medical systems) and Monte Carlo simulations. A multislit brass collimator consisting of 0.4 mm wide slits separated by a centre-to-centre distance of 4 or 6 mm was placed between the nozzle and the patient to shape the planar minibeams. For each plan, spread-out Bragg peaks and homogeneous dose distributions (±7% dose variations) can be obtained in target volumes. The Peak-to-Valley Dose Ratios (PVDR) were evaluated between 9.2 and 12.8 at a depth of 20 mm for meningioma and glioma, respectively. Dose volume histograms (DVHs) for target volumes and organs at risk were quantitatively compared, resulting in a slightly better target homogeneity with standard PT than with pMBRT plans, but similar DVHs for deep-seated organs-at-risk and lower average dose for shallow organs. The proposed delivery method evaluated in this work opens the way to an effective treatment for radioresistant tumours and will support the design of future clinical research.
质子微束放射治疗(pMBRT)是一种基于空间剂量分割的新型剂量传递方法。与标准照射相比,pMBRT 在减少副作用和提高高级别脑胶质瘤荷瘤大鼠的肿瘤控制方面显示出了很大的优势。这些发现,再加上最近在临床铅笔束扫描系统中对 pMBRT 的优化实施,引发了人们对其可能应用于患者治疗的思考。在这种情况下,本研究旨在对该技术的临床应用潜力进行首次理论研究。为此,开发了一种专用剂量引擎,并用于评估两种临床相关的患者治疗计划(高级别脑胶质瘤和脑膜瘤)。通过商业治疗计划系统(ECLIPSE-Varian Medical Systems)和蒙特卡罗模拟,对治疗计划与标准质子治疗计划进行了比较。在喷嘴和患者之间放置一个由 0.4 毫米宽狭缝组成的多狭缝黄铜准直器,狭缝之间的中心到中心距离为 4 或 6 毫米,以形成平面微束。对于每个计划,在靶区都可以获得扩展布拉格峰和均匀的剂量分布(±7%剂量变化)。脑膜瘤和脑胶质瘤在 20 毫米深度处的峰谷剂量比(PVDR)分别为 9.2 到 12.8。靶区和危及器官的剂量体积直方图(DVHs)进行了定量比较,结果表明标准 PT 计划的靶区均匀性略优于 pMBRT 计划,但深部危及器官的 DVHs 相似,浅层器官的平均剂量较低。本工作中评估的这种递药方法为治疗放射性抵抗肿瘤开辟了道路,并将支持未来临床研究的设计。